In today’s increasingly health-conscious world, weight loss is more than a trend – it’s a priority. To that end, GLP-1 drugs, renowned for their weight management efficacy, are expected to see demand surge, with the market projected to hit roughly $133 billion by 2030, expanding at a compound annual growth rate (CAGR) of 20%.
Big players like Novo Nordisk (NVO) and Eli Lilly and Company (LLY) are leading the charge on development, joined by retailers like Costco Wholesale Corporation (COST) and telehealth platforms like Hims & Hers Health, Inc. (HIMS) on distribution. The Kroger Co. (KR), a grocery chain, is also now stepping into the game, offering its journey to wellness through “The Little Clinic,” blending food and medicine to guide weight management. Embodying its “Food as Medicine” philosophy, this grocery giant is set to make GLP-1 drugs accessible to the masses.
